Sparks commentary

Healthcare

Sparks

GSK’s (LSE: GSK) five-in-one vaccine approved by the FDA
Published by Arron Aatkar, PhD

GSK’s five-in-one meningococcal vaccine, Penmenvy, has been approved by the US FDA for the treatment of meningitis, an indication that, in extreme cases, can lead to deadly brain swelling. More specifically, Penmenvy combines two components of two marketed inoculations (Bexsero and Menveo), protecting against five common disease-causing serogroups of Neisseria meningitidis. Ultimately, this broad coverage in one vaccine should lead to an improvement in vaccination rates and increase protection for adolescents and young adults in the US. Penmenvy is likely to be a main competitor against Pfizer’s Penbraya.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free